A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (pdgfrα) monoclonal antibody, in advanced soft tissue sarcoma (sts) Meeting Abstract
| Authors: | Tap, W.; Jones, R. L.; Chmielowski, B.; Elias, A. D.; Adkins, D.; Van Tine, B. A.; Agulnik, M.; Cooney, M.; Livingston, M. B.; Pennock, G.; Qin, A.; Shahir, A.; Ilaria, R.; Conti, I.; Schwartz, G. |
| Abstract Title: | A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (pdgfrα) monoclonal antibody, in advanced soft tissue sarcoma (sts) |
| Meeting Title: | 18th National Congress of Medical Oncology |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2016 Oct 28-30 |
| Meeting Location: | Rome, Italy |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-09-12 |
| Start Page: | iv98 |
| Language: | English |
| ACCESSION: | WOS:000393829200309 |
| DOI: | 10.1093/annonc/mdw343.01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P01 -- Source: Wos |
